Drug level of resistance of emerging SARS-CoV-2 variations is also a problem as exemplified from the action from the FDA in January 2022 to limit the usage of the anti-S mAb cocktail of bamlanivimab and etesevimab, aswell while the mAb cocktail of imdevimab and casirivimab in COVID-19 individuals, as both these mAb cocktails aren’t dynamic against the Omicron version, that was circulating in america at an extremely high frequency at that best period [31] April 2, 2023 nanokersociety Drug level of resistance of emerging SARS-CoV-2 variations is also a problem as exemplified from the action from the FDA… Continue Reading →